Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL-induced osteoclast differentiation

Hajime Yoshida, Kuniaki Okamoto, Tsutomu Iwamoto, Eiko Sakai, Kazuhiro Kanaoka, Jin Ping Hu, Mitsue Shibata, Hitoshi Hotokezaka, Kazuhisa Nishishita, Akio Mizuno, Yuzo Kato

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Pepstatin A is well known to be an inhibitor of aspartic proteinases such as pepsin, cathepsins D and E. Except for its role as a proteinase inhibitor, however, the pharmacological action of pepstatin A upon cells remain unclear. In this study, we found that pepstatin A suppressed receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation. Pepstatin A suppressed the formation of multinuclear osteoclasts dose-dependently. This inhibition of the formation only affected osteoclast cells, i.e., not osteoblast-like cells. Furthermore, pepstatin A also suppressed differentiation from pre-osteoclast cells to mononuclear osteoclast cells dose-dependently. This inhibition seems to be independent of the activities of proteinases such as cathepsin D, because the formation of osteoclasts was not suppressed with the concentration that inhibited the activity of cathepsin D. Cell signaling analysis indicated that the phosphorylation of ERK was inhibited in pepstatin A-treated cells, while the phosphorylation of IκB and Akt showed almost no change. Furthermore, pepstatin A decreased the expression of nuclear factor of activated T cells c1 (NFATc1). These results suggest that pepstatin A suppresses the differentiation of osteoclasts through the blockade of ERK signaling and the inhibition of NFATc1 expression.

Original languageEnglish
Pages (from-to)583-590
Number of pages8
JournalJournal of Biochemistry
Volume139
Issue number3
DOIs
Publication statusPublished - Mar 2006
Externally publishedYes

Fingerprint

Aspartic Acid Proteases
Osteoclasts
Cathepsin D
NFATC Transcription Factors
Phosphorylation
Cathepsin E
Peptide Hydrolases
Cell signaling
Somatostatin-Secreting Cells
pepstatin
Pepsin A
Osteoblasts
Cells
Pharmacology
Ligands

Keywords

  • Aspartic proteinase
  • Cathepsin
  • Osteoclast
  • Pepstatin A

ASJC Scopus subject areas

  • Biochemistry

Cite this

Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL-induced osteoclast differentiation. / Yoshida, Hajime; Okamoto, Kuniaki; Iwamoto, Tsutomu; Sakai, Eiko; Kanaoka, Kazuhiro; Hu, Jin Ping; Shibata, Mitsue; Hotokezaka, Hitoshi; Nishishita, Kazuhisa; Mizuno, Akio; Kato, Yuzo.

In: Journal of Biochemistry, Vol. 139, No. 3, 03.2006, p. 583-590.

Research output: Contribution to journalArticle

Yoshida, H, Okamoto, K, Iwamoto, T, Sakai, E, Kanaoka, K, Hu, JP, Shibata, M, Hotokezaka, H, Nishishita, K, Mizuno, A & Kato, Y 2006, 'Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL-induced osteoclast differentiation', Journal of Biochemistry, vol. 139, no. 3, pp. 583-590. https://doi.org/10.1093/jb/mvj066
Yoshida, Hajime ; Okamoto, Kuniaki ; Iwamoto, Tsutomu ; Sakai, Eiko ; Kanaoka, Kazuhiro ; Hu, Jin Ping ; Shibata, Mitsue ; Hotokezaka, Hitoshi ; Nishishita, Kazuhisa ; Mizuno, Akio ; Kato, Yuzo. / Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL-induced osteoclast differentiation. In: Journal of Biochemistry. 2006 ; Vol. 139, No. 3. pp. 583-590.
@article{b8b719f3b54a459f85bd6bc136046ae3,
title = "Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL-induced osteoclast differentiation",
abstract = "Pepstatin A is well known to be an inhibitor of aspartic proteinases such as pepsin, cathepsins D and E. Except for its role as a proteinase inhibitor, however, the pharmacological action of pepstatin A upon cells remain unclear. In this study, we found that pepstatin A suppressed receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation. Pepstatin A suppressed the formation of multinuclear osteoclasts dose-dependently. This inhibition of the formation only affected osteoclast cells, i.e., not osteoblast-like cells. Furthermore, pepstatin A also suppressed differentiation from pre-osteoclast cells to mononuclear osteoclast cells dose-dependently. This inhibition seems to be independent of the activities of proteinases such as cathepsin D, because the formation of osteoclasts was not suppressed with the concentration that inhibited the activity of cathepsin D. Cell signaling analysis indicated that the phosphorylation of ERK was inhibited in pepstatin A-treated cells, while the phosphorylation of IκB and Akt showed almost no change. Furthermore, pepstatin A decreased the expression of nuclear factor of activated T cells c1 (NFATc1). These results suggest that pepstatin A suppresses the differentiation of osteoclasts through the blockade of ERK signaling and the inhibition of NFATc1 expression.",
keywords = "Aspartic proteinase, Cathepsin, Osteoclast, Pepstatin A",
author = "Hajime Yoshida and Kuniaki Okamoto and Tsutomu Iwamoto and Eiko Sakai and Kazuhiro Kanaoka and Hu, {Jin Ping} and Mitsue Shibata and Hitoshi Hotokezaka and Kazuhisa Nishishita and Akio Mizuno and Yuzo Kato",
year = "2006",
month = "3",
doi = "10.1093/jb/mvj066",
language = "English",
volume = "139",
pages = "583--590",
journal = "Journal of Biochemistry",
issn = "0021-924X",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL-induced osteoclast differentiation

AU - Yoshida, Hajime

AU - Okamoto, Kuniaki

AU - Iwamoto, Tsutomu

AU - Sakai, Eiko

AU - Kanaoka, Kazuhiro

AU - Hu, Jin Ping

AU - Shibata, Mitsue

AU - Hotokezaka, Hitoshi

AU - Nishishita, Kazuhisa

AU - Mizuno, Akio

AU - Kato, Yuzo

PY - 2006/3

Y1 - 2006/3

N2 - Pepstatin A is well known to be an inhibitor of aspartic proteinases such as pepsin, cathepsins D and E. Except for its role as a proteinase inhibitor, however, the pharmacological action of pepstatin A upon cells remain unclear. In this study, we found that pepstatin A suppressed receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation. Pepstatin A suppressed the formation of multinuclear osteoclasts dose-dependently. This inhibition of the formation only affected osteoclast cells, i.e., not osteoblast-like cells. Furthermore, pepstatin A also suppressed differentiation from pre-osteoclast cells to mononuclear osteoclast cells dose-dependently. This inhibition seems to be independent of the activities of proteinases such as cathepsin D, because the formation of osteoclasts was not suppressed with the concentration that inhibited the activity of cathepsin D. Cell signaling analysis indicated that the phosphorylation of ERK was inhibited in pepstatin A-treated cells, while the phosphorylation of IκB and Akt showed almost no change. Furthermore, pepstatin A decreased the expression of nuclear factor of activated T cells c1 (NFATc1). These results suggest that pepstatin A suppresses the differentiation of osteoclasts through the blockade of ERK signaling and the inhibition of NFATc1 expression.

AB - Pepstatin A is well known to be an inhibitor of aspartic proteinases such as pepsin, cathepsins D and E. Except for its role as a proteinase inhibitor, however, the pharmacological action of pepstatin A upon cells remain unclear. In this study, we found that pepstatin A suppressed receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation. Pepstatin A suppressed the formation of multinuclear osteoclasts dose-dependently. This inhibition of the formation only affected osteoclast cells, i.e., not osteoblast-like cells. Furthermore, pepstatin A also suppressed differentiation from pre-osteoclast cells to mononuclear osteoclast cells dose-dependently. This inhibition seems to be independent of the activities of proteinases such as cathepsin D, because the formation of osteoclasts was not suppressed with the concentration that inhibited the activity of cathepsin D. Cell signaling analysis indicated that the phosphorylation of ERK was inhibited in pepstatin A-treated cells, while the phosphorylation of IκB and Akt showed almost no change. Furthermore, pepstatin A decreased the expression of nuclear factor of activated T cells c1 (NFATc1). These results suggest that pepstatin A suppresses the differentiation of osteoclasts through the blockade of ERK signaling and the inhibition of NFATc1 expression.

KW - Aspartic proteinase

KW - Cathepsin

KW - Osteoclast

KW - Pepstatin A

UR - http://www.scopus.com/inward/record.url?scp=33646357266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646357266&partnerID=8YFLogxK

U2 - 10.1093/jb/mvj066

DO - 10.1093/jb/mvj066

M3 - Article

VL - 139

SP - 583

EP - 590

JO - Journal of Biochemistry

JF - Journal of Biochemistry

SN - 0021-924X

IS - 3

ER -